Early trial tests experimental vaccine for Tough-to-Treat breast cancer
NCT ID NCT02157051
Summary
This early-stage study is testing the safety and immune response of a new vaccine called STEMVAC in patients with advanced HER2-negative breast cancer. The vaccine aims to train the body's immune system to recognize and attack cancer cells, particularly those that are resistant to chemotherapy. Researchers are testing different dosing schedules in 42 patients who have already completed standard treatments and have either no evidence of disease or stable bone-only disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.